CAPELLO JEFFREY D 4

What Happened
Jeffrey D. Capello, a director of Agios Pharmaceuticals (AGIO), reported the conversion/exercise of 1,976 derivative units on June 13, 2026. The filing shows 1,976 shares acquired at $0.00 (conversion of derivative) and the same 1,976 shares reported as disposed at $0.00. No cash value is recorded for these entries (total reported value $0).

Key Details

• Transaction date: 2026-06-13; Filing date: 2026-06-16 (timely filing).
• Reported activity codes: M = exercise/conversion of a derivative.
• Shares acquired: 1,976 @ $0.00 (total $0). Shares disposed: 1,976 @ $0.00 (total $0).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — each restricted stock unit (RSU) converts to one common share. F2 — RSUs granted 06/13/2023, vest in three equal annual installments beginning 06/13/2024; vested shares are delivered within three business days after vesting.
• The filing does not state the reason for the simultaneous acquisition and disposition recorded at $0.00.

Context
This filing reflects RSU conversion/vesting mechanics rather than an open-market purchase or sale. Retail investors should note this is not a market sale for liquidity insight; it documents the conversion/delivery process tied to long-term equity awards.